A review of the psychometric performance of selected child and adolescent preference-based measures used to produce utilities for child and adolescent health by Rowen, D. et al.
This is a repository copy of A review of the psychometric performance of selected child 
and adolescent preference-based measures used to produce utilities for child and 
adolescent health.




Rowen, D. orcid.org/0000-0003-3018-5109, Keetharuth, A., Poku, E. et al. (3 more 
authors) (2020) A review of the psychometric performance of selected child and 
adolescent preference-based measures used to produce utilities for child and adolescent 





This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 
(CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long 
as you credit the authors, but you can’t change the article in any way or use it commercially. More 
information and the full terms of the licence here: https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
- Contents lists available at sciencedirect.com
Journal homepage: www.elsevier.com/locate/jval
A Review of the Psychometric Performance of Selected Child and
Adolescent Preference-Based Measures Used to Produce Utilities for Child
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A B S T R A C T
Objective: This review examined the psychometric performance of 4 generic child- and adolescent-specific preference-based
measures that can be used to produce utilities for child and adolescent health.
Methods: A systematic search was undertaken to identify studies reporting the psychometric performance of the Child Health
Utility (CHU9D), EQ-5D-Y (3L or 5L), and Health Utilities Index Mark 2 (HUI2) or Mark 3 (HUI3) in children and/or
adolescents. Data were extracted to assess known-group validity, convergent validity, responsiveness, reliability,
acceptability, and feasibility. Data were extracted separately for the dimensions and utility index where this was reported.
Results: The review included 76 studies (CHU9D n = 12, EQ-5D-Y-3L n = 20, HUI2 n = 26,HUI3 n = 43), which varied
considerably across conditions and sample size. EQ-5D-Y-3L had the largest amount of evidence of good psychometric
performance in proportion to the number of studies examining performance. The majority of the evidence related to EQ-
5D-Y-3L was based on dimensions. CHU9D was assessed in fewer studies, but the majority of studies found evidence of
good psychometric performance. Evidence for HUI2 and HUI3 was more mixed, but the studies were more limited in
sample size and statistical power, which was likely to have affected performance.
Conclusions: The heterogeneity of published studies means that the evidence is based on studies across a range of countries,
populations and conditions, using different study designs, different languages, different value sets and different statistical
techniques. Evidence for CHU9D in particular is based on a limited number of studies. The findings raise concerns about the
comparability of self-report and proxy-report responses to generate utility values for children and adolescents.
Keywords: adolescents, children, CHU9D, EQ-5D-Y-3L, HUI2, HUI3, paediatric, QALYs, utilities.
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Introduction
Health technology assessment (HTA) can be used as a tool for
informing resource allocation decisions by assessing the cost-
effectiveness of interventions and enabling comparisons of rela-
tive cost-effectiveness across a range of interventions for different
conditions and populations. The quality-adjusted life-year (QALY)
is commonly used to capture the benefit of interventions for use in
HTA. QALY is calculated by quality-weighting survival using a
quality adjustment, which is often generated using a generic
preference-based measure. A preference-based measure consists
of a classification system and a value set that is used to score re-
sponses to the classification system. The classification system
contains dimensions with severity levels. Responses to the clas-
sification system are used to assign people to a health state. A
value set is then used to score the relative value of the health state
to generate a utility value (index score), on the 1-to-0 full health–
dead scale, with values less than zero indicating that the health
state is worse than being dead. There are many different
preference-based measures available, and these can be condition-
specific or generic, and population-specific (eg, adults or children)
or suitable across many populations.
Measures for estimating adult health utilities are often
assessed by reference to the psychometric performance of mea-
sures, such as assessing their validity and responsiveness in
particular populations. The psychometric performance of the main
generic preference-based measures has been assessed widely in
the published literature, and there is a published review of re-
views about their performance.1 This means that both researchers
and decision makers have knowledge about the appropriateness
of the utility values generated by these measures across a range of
conditions and also about whether the measure would be
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expected to identify a statistically significant change in that pop-
ulation. This can provide valuable information about the confi-
dence in the utility estimates and interpretation of changes in
utility values; however, to our knowledge there is no review of the
published literature examining the psychometric performance of
the child and adolescent preference-based measures.
One existing review examined the development and applica-
tion of generic preference-based measures available for use in
pediatric populations2 and found 9 measures (Adolescent Health
Utility Measure, Assessment of Quality of Life [AQoL-6D], Child
Health Utility [CHU9D], EQ-5D-Y-3L, Health Utilities Index Mark 2
(HUI2) and Mark 3 (HUI3), 16D, 17D, and the Quality of Wellbeing
Scale [QWB]); researchers concluded that further empirical ana-
lyses are required to examine the relative performance of these
measures. One review examined the valuation methods used to
generate the values sets of these preference-based measures.3
Another review found that 7 of these preference-based measures
had been commonly used internationally in pediatric populations:
AQoL-6D, EQ-5D-Y-3L, CHU9D, HUI2, HUI3, 15D/16D/17D, and
QWB.4 This review4 provided a fully comprehensive source of
published utility values from the existing literature across a range
of conditions but did not assess the psychometric performance of
the measures used to generate the utility values.
The present review examined the psychometric performance
of a selection of generic child and adolescent-specific preference-
based measures that can be used to generate utility values for
children and adolescents: CHU9D, EQ-5D-Y-3L, HUI2, and HUI3.
Methods
Description of Measures
The measures selected for inclusion in the reviewwere CHU9D,
EQ-5D-Y-3L, HUI2, and HUI3 because the authors, after consulta-
tion with National Institute for Health and Care Excellence staff,
considered these to be the measures most appropriate to inform
UK policy using criteria about intended and worded appropriately
for use in children and adolescents, applicability across conditions
using a generic classification system of dimensions and levels,
development (or validation) with an English-speaking population,
and potential availability in datasets used to inform UK policy.
Following is a summary of each of the child- and adolescent-
specific preference-based measures examined in the review.
CHU9D
The CHU9D has 9 dimensions each with 5 severity levels:
worry, sadness, pain, tiredness, annoyance, school, sleep, daily
routine, and activities. The dimensions and severity levels were
developed using qualitative research with children aged 7 to 11
years and hence were designed for this age group; however, the
measure can be completed via parent/guardian proxy for children
aged 4 to 7 years and has been used in adolescents aged 12 to 18
years. Value sets exist for the UK,5 Australia,6-9 The Netherlands,10
and China.11
EQ-5D-Y-3L and EQ-5D-Y-5L
The EQ-5D-Y is the youth version of the EQ-5D. The EQ-5D-Y
was generated by adapting the adult EQ-5D to ensure relevance
and clarity for children and adolescents.12-14 The same 5 di-
mensions of the adult EQ-5D are each retained in the EQ-5D-Y, but
the dimensions and levels were reworded to be appropriate for
children by an international team of collaborators. The EQ-5D-Y-3L
has 5 dimensions each with 3 levels of severity: mobility; looking
after myself; doing usual activities; having pain or discomfort; and
feeling worried, sad or unhappy. There is also a more recent 5-
level youth version of the EQ-5D called the EQ-5D-Y-5L.15 There
is no officially accepted value set for the EQ-5D-Y-3L or EQ-5D-Y-
5L, though there is a published value set for the EQ-5D-Y-3L in the
United States.16 Recent research has found that current EQ-5D
value sets cannot be appropriately used to value EQ-5D-Y health
states.17,18 The EuroQol Group is currently developing an interna-
tional valuation protocol for the development of country-specific
EQ-5D-Y value sets.19
HUI2
The HUI2 has 7 dimensions: sensation, mobility, emotion,
cognition, self-care, pain, and fertility.20 Each dimension has be-
tween 3 and 5 levels. The measure was originally developed in
Canada for use in childhood cancer but is widely used as a generic
measure, although the fertility dimension is rarely used. The HUI2
has a UK value set21 and a Canadian value set20 and can be used to
measure health of children and adults aged 5 and over. HUI2 and
HUI3 are typically administered using a single set of 15 self-
administered questions, which are then used to generate both
HUI2 and HUI3 utilities. Interviewer administration of the set of
items used to generate both HUI2 and HUI3 utilities involves be-
tween 13 and 39 questions.
HUI3
The HUI3 was developed in Canada with the purpose of
resolving some issues faced with HUI2 and for applicability to
clinical and general populations. HUI3 has 8 dimensions: vision,
hearing, speech, ambulation, dexterity, emotion, cognition, and
pain.22 Each dimension has between 5 and 6 levels. The HUI3 has
only a Canadian value set.22 The HUI3 can be used to measure
health of children and adults aged 5 and older.
Search Strategy and Data Identification
The objective of the literature search was to identify relevant
published studies reporting evidence of the psychometric per-
formance of CHU9D, EQ-5D-Y (3L or 5L), HUI2, and HUI3 in chil-
dren and adolescents. A systematic search was conducted in
Medline (Ovid), PsycINFO (Ovid), and the Web of Science Core
Collection Science Citation Index Expanded (Clarivate Analytics) in
March and September 2019 to identify studies reporting the
psychometric performance of EQ-5D-Y (3L or 5L), CHU9D, HUI2,
AQoL-6D, and HUI3 in children and adolescents. Terms for the
measure (eg, “EQ-5D-Y,” “HUI,” “CHU9D”) were combined with
“child” population terms derived from a recently published sys-
tematic review of child utilities (which did not assess psycho-
metric performance of measures).4 The search strategy was
translated across each database, and limits for human studies and
English language were applied. No study type or publication date
limits were applied.
Supplementary gray literature searches included the confer-
ence abstract websites in the last 3 years (The International So-
ciety for Pharmacoeconomics and Outcomes Research and
International Society for Quality of Life Research), Web of Science
Cited Reference Search, keyword searching using Google Scholar
search engine, and examination of reference lists of included
studies.
The criteria for inclusion were an assessment of known-group
validity, convergent validity, responsiveness, reliability, accept-
ability or feasibility of EQ-5D-Y (3L or 5L), CHU9D, HUI2, or HUI3;
obtained from pediatric populations or relevant parents/care-
givers acting as proxies for children; with analyses reported
separately for participants aged younger than 18 years. The search
included the AQoL-6D and EQ-5D-Y-5L measures but identified
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only 1 relevant study each for AQoL-6D23 and EQ-5D-Y-5L,24
meaning that AQoL-6D and EQ-5D-Y-5L were post hoc exclusions
from the review.
Retrieved records were screened by 1 of 3 reviewers, with a 10%
randomly selected sample of titles and abstracts double checked by
a second reviewer. Full-text papers of potentially relevant records
wereobtained andexamined indetail. Study selectionwas basedon
predefined eligibility criteria. Summary data relating to study and
population characteristics was extracted by 1 of 2 reviewers and
checked by a second reviewer for all papers. Subsequently, 2 re-
viewers independently double extracted the psychometric analyses
for3 randomlyselectedpapersand, after comparingextractionsand
amendedusing consensus (differences occurred only in the amount
of detail extracted), undertook single extraction of the psycho-
metric data of the remaining papers.
Analytic Strategy
Assessments of the psychometric performance of patient-
reported outcome measures (PROMs) focus on validity, reliability
and responsiveness,25 though not all aspects that are relevant for
PROMs are relevant for preference-based measures. For example,
internal consistency reliability examines whether items within a
measure are measuring the same construct, which is important for
a PROM but not for a preference-based measure. We focused on
the aspects of reliability, validity, and responsiveness that are
important for assessing the performance of preference-based
measures1,26,27 and assessments of feasibility and acceptability.
We included both the performance of the utility index and di-
mensions where this information was available. Data were
extracted about the following:
 Measure(s): preference-based measure(s) used; language
version; whether the measure was self-reported and/or proxy
reported by parents/caregivers or both; whether the paper
assessed the index (ie, the utility scores generated by the mea-
sure), dimensions, or both index and dimensions; country pref-
erence weights applied (where applicable); other health-related
quality of life (HRQL) measures or clinical measures used.
 Study sample: age of participants (mean age and age range);
proportion of female participants; whether the sample con-
sisted of members of the general population, patients, or both;
clinical area (where applicable); sample size.
 Known-group validity: assesses the ability to differentiate be-
tween groups of different severity28 or a less rigorous test of
case-control construct validity that examines the ability to
differentiate between people with and without the condition;
determined using the ability to identify a reported statistically
significance difference at the 5% level across known groups,
along with whether the direction of the difference is in accor-
dance with clinical expectation (eg, general population with
higher utilities than patients). Where studies assess dimensions,
it is not typically expected that all dimensions will necessarily
capture known-group differences because not all conditions
affect all dimensions.
 Convergent validity: assesses the strength of association be-
tween the measure of interest and other measures of HRQL
(generic or condition-specific) or disease severity using either
correlation coefficients29 (a more conventional technique) or
statistical significance in regression analyses. Evidence of
convergent validity is determined by whether moderate (0.41-
0.60) or good (0.61-0.80) (or higher and almost perfect)
agreement has been identified. These are arbitrary cut-offs but
are often reported in the papers included in the review (and
based on established criteria; see, eg, Landis and Koch [1977]).30
Evidence of convergent validity focuses on expected correla-
tions where these are motivated in theory (eg, pain dimensions
in 2 measures).
 Responsiveness: assesses the ability to capture change over time,
where change is expected (eg, as a result of treatment effects).31
Evidence of responsiveness is determined by the ability to
determine a statistically significance change at the 5% level over
time. It also considers whether the direction of the change is in
accordance with clinical expectation (eg, higher index scores at
the end of treatment than at baseline). Where dimensions are
assessed, it is not necessarily expected that all dimensions will
be responsive because not all conditions or treatments affect all
dimensions.
 Reliability: assesses the degree of change where no change in
health is identified using other HRQL or clinical measures. Evi-
dence of reliability is determined bywhether themeasure is able
to reproduce the same value on 2 separate administrationswhen
there has been no change in health, where this can be over time
(test-retest reliability),32 between methods of administration
(intermodal reliability) or between raters (ie, self-report and
parent proxy report [interrater reliability]).33 Reliability is
sometimes identified for most but not all dimensions, but if
reliability is not identified for some dimensions, this raises issues
about reliability of the entire measure.
 Acceptability and feasibility: assess the practicality of a measure
for administration in a specific group of people, covering as-
pects such as burden of completion and whether the person
completing the measure can meaningfully respond to the
questions being asked. Evidence of acceptability and feasibility
is indicated where the study reports, for example, low missing
data or high levels of understanding. A lack of evidence for
acceptability and feasibility is concluded where the study re-
ports, for example, high levels of missing data or low levels of
understanding. For child and adolescent measures this includes
whether the child and adolescent or the proxy can meaningfully
complete the measure, because there may be problems of un-
derstanding for younger people and problems of knowing the
required information (eg, how the child feels emotionally) for
proxy report.
 Other psychometric analyses reported.
Where reported, data were extracted for each of the psycho-
metric assessments about brief summary of analysis undertaken,
whether the results were in accordance with clinical expectation




A total of 1218 unique records were identified, with 8 addi-
tional records identified from reference lists. Of these, 102 records
were examined in detail. After the exclusion of 26 papers (see
Supplemental Table found at https://doi.org/10.1016/j.jval.2020.
09.012), 76 papers, including 72 full-text articles and 4 confer-
ence abstracts,34-37 were considered suitable for providing evi-
dence for the psychometric assessment of EQ-5D-Y-3L, CHU9D,
HUI2, and HUI3. A PRISMA flow chart of the study selection pro-
cess is shown in Figure 1.
Included Studies
Characteristics of included studies are summarized in Table 1,
and further details are provided in the Supplemental Table (found
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at https://doi.org/10.1016/j.jval.2020.09.012). Out of the 76 studies,
53 studies assess only 1 of the child- and adolescent-specific
preference-based measures assessed here. Nineteen studies
assess both HUI2 and HUI3,34,38-54 2 studies assess CHU9D and
EQ-5D-Y-3L,55,56 1 assesses EQ-5D-Y-3L and HUI2,57 and 1 assesses
CHU9D and HUI2.7,58 Forty-two studies assess HUI3, 26 studies
assess HUI2, 20 studies assess EQ-5D-Y-3L, and 12 studies assess
CHU9D. One study24 compares EQ-5D-Y-3L and EQ-5D-Y-5L.
Value Sets
CHU9D studies use the UK value set (n = 9), Australian
adolescent value set (n = 4), Australian adult value set (n = 2). EQ-
5D-Y-3L has no accepted value set, meaning that 15 studies do not
generate utility scores. The remaining 5 studies assessing EQ-5D-
Y-3L scored health states using the UK, Australian, French, and
Spanish value sets for the EQ-5D and an unofficial US EQ-5D-Y-3L
value set (1 study each). Twenty studies used the Canadian HUI2
value set, 2 used the UK value set, 3 did not use a value set, and 1
did not report the value set used. The HUI3 only has a Canadian
value set, though 4 studies reported results for dimensions only.
Country and Language
The data assessed in the studies are from a variety of countries,
with Canada (n = 16), the UK (n = 12), the United States (n = 9), and
Australia (n = 8) having the largest number of included studies,
followed by The Netherlands (n = 4), Sweden (n = 4), Spain (n = 3),
China (n = 2), Germany (n = 2), South Africa (n = 2), and many
countries with 1 study (France, Hong Kong, Italy, New Zealand,
South Korea, Taiwan, Thailand, and Turkey), 2 multinational
studies (each included Germany, Italy, South Africa, Spain, and
Sweden), 1 study in Australia and New Zealand, 1 study in the UK
and Ireland, 1 study in the UK and the United States, and 1 study in
which the country was not reported. A large number of studies
used the English language version of the measures: CHU9D (n =
11), EQ-5D-Y-3L (n = 6), HUI2 (n = 22), HUI3 (n = 34).
Study Population and Condition
The majority of studies assessed a clinical population (n = 48),
though some studies assessed the measure using only a general
population sample (n = 15) and other studies compared general
population and clinical population samples (n = 13). A wide range
of conditions were covered in the studies. Conditions assessed in
at least one study include asthma (n = 3), cancer (n = 5), cerebral
palsy (n = 3), children born with extremely low birth weight (n =
3), chronic illness (n = 3), chronic kidney disease (n = 2), deafness
(n = 2) and permanent hearing loss (n = 1), depression (n = 2),
Hodgkin disease (n = 2), overweight and obesity (n = 2), stutter
(n = 2), and type 1 diabetes mellitus (n = 2).
Figure 1. PRISMA flow chart.
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Table 1. Characteristics of included studies.
Study
reference














UK UK Yes No Yes No 6-7 160
Chen, 201556 Australia Australia adult Yes No Yes No 11-17 2020
Foster Page,
201567




Yes No 6-9 87
Frew, 201568 UK UK Yes Underweight,
healthy weight,
overweight or obese
Yes No 5-6 1344





No Yes 5-17 200
Oluboyede,
201970





Yes No Yes No 15-17 775
Ratcliffe,
2012a58






Yes No Yes No 11-17 500
Sach, 201736 UK UK No Eczema N/R N/R $5 137
Stevens,
2012a72
Australia UK Yes No Yes No 11-17 961
Xu, 201473 China UK and
Australian
adolescent
Yes No Yes No 9-19 815
EQ-5D-Y-3L
Åström, 201874 Sweden No Yes No Yes No 13-18 6574
Bergfors,
201564
Sweden No No Asthma Yes No 8-16 94
Burstrom,
201475
Sweden No Yes Functional motor,
orthopedic and
medical disabilities






UK UK EQ-5D Yes No Yes No 6-7 160
Chen, 201556 Australia Australia EQ-5D Yes No Yes No 11-17 2020
Eidt-Koch,
200976
Germany No No Cystic fibrosis Yes Yes 8-17 96
Hernandez,
201535
Spain France EQ-5D No Asthma Yes No 6-11 69
Hsu, 201877 Taiwan No No Chronic kidney
disease
Yes No 7-18 68
Jelsma, 201078 South Africa No Yes No Yes No N/R 522
Kim, 201863 South Korea No No Allergic conditions Yes No 7-13 9949
Loof, 201979 Sweden No Yes Idiopathic clubfoot Yes Yes 8-10 215
Mayoral,
201737
Unknown Spain EQ-5D No Type 1 diabetes
mellitus
N/R N/R N/R 136
Oluboyede,
201357
UK No Yes No Yes No 11-18 49
Perez-Sousa,
201880
Spain No No Overweight and
obese
Yes Yes 6-14 151





















No Yes No Yes No $8 2809
Robles, 201581 Spain No Yes No Yes No 8-18 923
Scalone, 201182 Italy No Yes Acute lymphoblastic
leukemia
Yes No 8-15 440
Scott, 201783 South Africa USA Yes Acutely ill or chronic
health condition/
disability
Yes No 8-12 329
Wille, 201014 Germany, Italy, South
Africa, Spain, Sweden
No Yes No Yes No 8-18 1987
Wong, 201924 China No No Adolescent or
juvenile idiopathic
scoliosis
Yes No 8-17 129
HUI2
Banks, 200838 Canada Canada No Cancer—undergoing
chemotherapy
Yes ($10) Yes 2-18 29
Barr, 199739 Canada Canada No Cancer Yes† Yes N/R 18
Belfort, 201140 USA Canada No Attending well-child
appointments or
obesity clinic
Yes Yes 5-18 76





No Yes 11 mo–14 yr 50
Dickerson,
201884
USA Canada No Depression Yes No 13-17 392
Feeny, 200442 Canada Canada Yes Extremely low weight
at birth
Yes No 12-16 275
Furlong, 201243 Canada Canada Yes Acute lymphoblastic
leukemia
Yes Yes 5-18 196
Glaser, 199985 UK Canada No Central nervous
system tumor
survivors
Yes Yes 6-16 30
Kennedy,
199986
UK Canada No Childhood brain
tumor survivors
Yes ($16) Yes (,16) 2-11 32
Klaassen,
2010a87
Canada Canada No Hodgkin disease Yes No 8-17 51
Klaassen,
2010b44
Canada Canada No Hodgkin disease Yes Yes 8.9-18 49
Kulpeng,
201345













France N/A No Medulloblastoma
and ependymoma
Yes Yes 5-19 43
Lynch, 201647 USA Canada Yes Depression Yes No 13-17 392
Mok, 201448 Hong Kong Canada No Down syndrome No Yes 5-18 30
Morrow,
201249
Australia N/A No Chronic illness Yes ($12
and able)
Yes 5-18 131
continued on next page


















Canada Canada No Childhood cancer
survivors
No Yes 7-16 250
Oluboyede,
201357
UK No Yes No Yes No 11-18 49
Petrou, 201351 UK and Republic of
Ireland
UK Yes Neurologic disability
and preterm births
No Yes Clinical population
10 yr 1 mo–11 yr 1
mo
General population 9




Australia UK Yes No Yes No 11-17 500
Stevens,
2012b34
UK UK No Intensive care Yes (.11) Yes $5 685
Sung, 200352 Canada Canada No Cancer No Yes 1-18 36
Sung, 200453 Canada Canada No Chronic illness Yes Yes 12-17 19
Trevino, 201354 USA Canada Yes Obesity Yes No 10-12 4979
Trudel, 199888 Canada Canada No Cancer No Yes 4-18 61






Banks, 200838 Canada Canada No Cancer—undergoing
chemotherapy
Yes ($10) Yes 2-18 29
Barr, 199739 Canada Canada No Cancer Yes‡ Yes N/R 18
Belfort, 201140 USA Canada No Attending well-child
appointments or
obesity clinic
Yes Yes 5-18 76





No Yes 11 mo–14 yr 50
Boulton, 200689 England Canada No Vision impairment or
blindness
Yes Yes 3-8 79








The Netherlands Canada No Stutter Yes Yes 3-6.3 198
Dickerson,
201884
USA Canada No Depression Yes No 13-17 392
Feeny, 200442 Canada Canada Yes Extremely low weight
at birth
Yes No 12-16 275
Francis, 201993 Australia
New Zealand
Canada No Chronic kidney
disease
Yes ($13) Yes (,13) 6-18 375
Furlong, 201243 Canada Canada Yes Acute lymphoblastic
leukemia
Yes Yes 5-18 196








Yes Yes 10-17 60
















Kennes, 200295 Canada N/A No Cerebral palsy Yes Yes 5-13 408
Klaassen,
2010a87
Canada Canada No Hodgkin disease Yes No 8-17 51
Klaassen,
2010b44
Canada Canada No Hodgkin disease Yes Yes 8.9-18 49
Kulkarni,
201096
Canada Canada No Obstructive
hydrocephalus
No Yes 5-18 47
Kulpeng,
201345













France N/A No Medulloblastoma
and ependymoma
Yes Yes 5-19 43
Lee, 201197 USA Canada No Type 1 diabetes Yes Yes 8-18 238
Livingston,
200859
Canada Canada No Cerebral palsy No Yes 13-20 185
Lovett,
201047,98
UK Canada No Deafness No Yes 18 mo–16 yr 50
Lynch, 201647 USA Canada Yes Depression Yes No 13-17 392






Mok, 201448 Hong Kong Canada No Down syndrome No Yes 5-18 30
Morrow,
201249






Canada Canada No Childhood cancer
survivors
No Yes 7-16 250
Penn, 201199 UK Canada Yes Childhood brain
tumors
Yes ($8) Yes 3-16 61





No Yes Clinical population
10 yr 1 mo–11 yr 1
mo
General population 9




USA Canada No Adolescents with BMI
$ 85th percentile
with type 2 diabetes,
prediabetes or
insulin resistance
Yes Yes 12-18 107
Roposch,
2011101




dysplasia of the hip
Yes No 4-18 72
Rosenbaum,
200760
Canada Canada No Cerebral palsy No Yes 13-20 203
Smith-Olinde,
2008102
USA Canada No Permanent hearing
loss
No Yes 5-10 103





Yes Yes 8-21 126
continued on next page
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Self-report and Proxy Report
Thirty studies administered the measures to the children/ad-
olescents using only self-report, and 14 studies administered the
measures using only proxy report. Twenty-seven studies used
both self-report and proxy report for the same children, though
for 11 of these studies restrictions were given about when self-
complete was administered (eg, a minimum age or only where
the child was able to self-complete), and one of the studies
administered the measures separately and then as a dyad. Three
studies used either self- or proxy report depending on the age of
the child, and 2 studies did not report who completed the
measure.
Age and Gender
Mean age varied from 6.4 years55 to 16.59,60 The age range of
children and adolescents included in each study varied. Eleven
studies included children aged younger than 5 years, which is
younger than the recommended age for the measures used in
these studies (note the minimum recommended age for CHU9D
and EQ-5D-Y-3L is 4 and for HUI2 and HUI3 is 5).3 The percentage
of female participants in the samples ranged from 14.7%61 to
80.6%.24
Sample Size
Sample size varied considerably, from 7 participants62 to
9949.63 Thirteen studies had sample sizes less than 50, 15 studies
had sample sizes between 50 and 99, and 7 studies had sample
sizes of 1000 or more.
Psychometric Performance
No study assesses all properties extracted in this review.
Overall 48 studies assessed known-group validity, 33 studies
assessed convergent validity, 14 studies assessed responsiveness,
24 studies assessed reliability, and 19 studies assessed accept-
ability and feasibility. Table 2 summarizes whether the study
found evidence, mixed evidence, or no evidence for each of the
properties assessed per measure, ordered within each measure by
population assessed (general population, clinical population, or
whether both general and clinical populations are assessed). For
CHU9D the review found evidence of known-group validity,
convergent validity, acceptability and feasibility, and mixed evi-
dence of responsiveness, but the only study assessing test-retest
reliability did not find evidence of reliability. For EQ-5D-Y-3L di-
mensions, the review found evidence of known-group validity,
convergent validity, responsiveness, acceptability, and feasibility
and mixed evidence of test-retest reliability, but the only study
assessing interrater reliability did not find evidence of reliability.
The evidence was mainly about the performance of the di-
mensions because there is no recommended value set. For HUI2
the review found evidence of convergent validity and test-retest
reliability and mixed evidence of known-group validity, respon-
siveness, interrater reliability, acceptability, and feasibility because
good performance was not found unanimously across these as-
pects of psychometric performance. For HUI3 the review found
evidence of convergent validity and mixed evidence of known-
group validity, responsiveness, interrater reliability, test-retest
reliability, and acceptability and feasibility, with a proportion of
studies not reporting evidence of known-group validity, respon-
siveness, or reliability.
Performance by Study Population
For CHU9D the most evidence was about performance in a
general population sample (n = 8), and performance appeared
similar across clinical and general population samples. For EQ-5D-

















UK Canada No Intensive care Yes (.11) Yes 5 and older 685
Sung, 200352 Canada Canada No Cancer No Yes 1-18 36
Sung, 200453 Canada Canada No Chronic Illness Yes Yes 12-17 19
Tan, 2018104 Australia Canada No Part of an obesity
prevention
intervention
No Yes 2-5 (unclear) 368
Tilford, 201261 USA Canada Yes Autism spectrum
disorders
No Yes 4-17 150
Trevino, 201354 USA Canada Yes Obesity Yes No 10-12 4979







Netherlands Canada No Very low birth weight
children
Yes Yes 14 684






Note. Wong et al (2019) compare the EQ-5D-Y 3-level and 5-level versions.
BMI indicates body mass index; CHU9D, Child Health Utility; HUI2, Health Utilities Index Mark 2; HUI3, Health Utilities Index Mark 3; N/A, not applicable; N/R, not
reported.
*General population is recorded where the sample was recruited from the general population, and studies that are included both in the general population column and
in the condition column, where relevant, compare the performance of the measure in a clinical population sample to a general population sample.
†Excluded from the analysis because of low numbers.
‡These data cannot be extracted because they were merged with caregiver report up to aged 26.
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Both General 160 U U 7 U
Chen, 201556 Both General 2020 U U
Oluboyede,
201970
Index General 975 U U
Petersen,
201871
Index General 775 U U
Ratcliffe,
2012a58
Both General 500 6 U
Ratcliffe,
2012b23
Index General 500 U
Stevens,
2012a72
Both General 961 U 6
Xu, 201473 Both General 815 U
Foster Page,
201567
Index Clinical 87 U 7
Furber,
201569
Both Clinical 200 U U
Sach, 201736 Index Clinical 137 U U U




Dimensions General 6574 U
Canaway,
201355
Both General 160 U U 7 U
Chen, 201556 Both General 2020 U U
Jelsma,
201078
Dimensions General 522 U
Oluboyede,
201357




Dimensions General 2809 6 U U U
Robles,
201581
Dimensions General 923 U U
Wille, 201014 Dimensions General 1987 U
Bergfors,
201564
Dimensions Clinical 94 U
Eidt-Koch,
200976
Dimensions Clinical 96 U
Hernandez,
201535
Index Clinical 69 U
Hsu, 201877 Dimensions Clinical 68 6
Kim, 201863 Dimensions Clinical 9949 U U
Mayoral,
201737
Both Clinical 136 6 U U
Perez-Sousa,
201880
Dimensions Clinical 151 U 7
Wong,
201924,
Dimensions Clinical 129 6
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Dimensions Both 478 U U
Loof, 201979 Dimensions Both 215 6
Scalone,
201182
Dimensions Both 440 6 U U U




Dimensions General 49 7
Ratcliffe,
2012a58
Both General 500 6 U
Trevino,
201354
Index General 4979 6
Banks,
200838
Index Clinical 29 6 7
Barr, 199739 Both Clinical 18 U
Belfort,
201140
Both Clinical 76 7
Boran,
201141
Both Clinical 50 U U
Dickerson,
201884
Index Clinical 392 U U
Glaser,
199985
Index Clinical 30 U U
Kennedy,
199986
Index Clinical 32 6
Klaassen,
2010a87
Index Clinical 51 U 6
Klaassen,
2010b44
Index Clinical 49 6
Kulpeng,
201345
Index Clinical 173 U U
Le Gales,
199946
Dimensions Clinical 43 7 U
Lynch,
201647
Index Clinical 392 U
Mok, 201448 Index Clinical 30 U 1
Morrow,
201249




Both Clinical 250 U
Stevens,
2012b34
Index Clinical 685 † † U U
Sung, 200352 Both Clinical 36 6 U
Sung, 200453 Index Clinical 19 7
Trudel,
199888
Both Clinical 61 U U U
Ungar,
201265
Both Clinical 91 7 U 7 7 U
Feeny,
200442
Index Both 275 U U































Index Both 196 U 7
Petrou,
201351




Index General 4979 6
Banks,
200838
Index Clinical 29 6 7
Barr, 199739 Both Clinical 18 U U
Belfort,
201140
Both Clinical 76 7 6
Boran,
201141
Both Clinical 50 6 6
Boulton,
200689
Both Clinical 79 U
Cheng,
200090





Index Clinical 198 7
Dickerson,
201884
Index Clinical 392 U U
Francis,
201993
Both Clinical 375 U
Janse, 200894 Both Clinical 60 7
Kennes,
200295
Dimensions Clinical 408 U
Klaassen,
2010a87
Index Clinical 51 U 6
Klaassen,
2010b44
Index Clinical 49 6
Kulkarni,
201096
Index Clinical 47 U
Kulpeng,
201345
Index Clinical 173 U U
Le Gales,
199946
Dimensions Clinical 43 7 7 U
Lee, 201197 Index Clinical 238 U U U
Livingston,
200859
Index Clinical 185 7
Lovett,
201047,98
Index Clinical 50 7
Mattera,
201862
Dimensions Clinical 7 U
Mok, 201448 Index Clinical 30 U ‡
Morrow,
201249




Both Clinical 250 U
continued on next page
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population samples, with the same number of studies in each
population (n = 8 each, n = 4 for both clinical and general popu-
lation), though note that acceptability and feasibility was mainly
examined using a general population sample (6 of 9 samples
assessing feasibility). For HUI2 the majority of evidence was from
studies with clinical samples (n = 20), and the 3 studies using a
general population sample did not find evidence of good psy-
chometric performance. For HUI3 the majority of evidence was
from studies with clinical samples (n = 34), with only 1 study with
a general population sample, though studies with both general
and clinical population samples (n = 8) found evidence of known-
group validity and convergence validity in all studies where this
was assessed.
Summary of Psychometric Performance
Table 3 summarizes the results of all analyses. The number of
entries reflects the number of studies where each psychometric
property is assessed. EQ-5D-Y-3L has the largest amount of evi-
dence of good psychometric performance in proportion to the






























Index Clinical 107 7 U 6
Roposch,
2011101
Both Clinical 72 6 7
Rosenbaum,
200760




Both Clinical 103 7 U
Stade,
2006103
Both Clinical 126 6 U
Stevens,
2012b34
Index Clinical 685 1 † U U
Sung, 200352 Both Clinical 36 6 U
Sung, 200453 Index Clinical 19 7
Tan, 2018104 Both Clinical 368 7
Ungar,
201265
Both Clinical 91 7 U 7 7 7
Verrips,
2001105





Index Both 197 U
Feeny,
200442
Index Both 275 U U
Furlong,
201243
Index Both 196 U 7
Lynch,
201647
Index Both 392 U
Penn, 201199 Both Both 61 U 6
Petrou,
201351
Both Both 331 U
Tilford,
201261
Both Both 150 U U
Wolke,
2013106
Dimensions Both 554 U
Note. Wong et al (2019) compare the EQ-5D-Y 3-level and 5-level versions.
CHU9D indicates Child Health Utility; HUI2, Health Utilities Index Mark 2; HUI3, Health Utilities Index Mark 3.
U Evidence indicated significant performance. 7 Property was examined but no significant evidence was found. 6 Evidence was mixed or inconclusive evidence was
found.
*Sample size was reported for the reported sample assessed in the paper and may differ within the analyses reported.
†Property assessed but results not reported.
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performance (note this is for dimensions). The CHU9D was
assessed in fewer studies, but the majority of studies found evi-
dence of good psychometric performance. The evidence for HUI2
and HUI3 was more mixed. More detailed results are available in
the online Supplemental Table (found at https://doi.org/10.1016/j.
jval.2020.09.012), where studies can also be separated by
condition.
Discussion
The review outlined the evidence about the psychometric
performance of the child and adolescent-specific measures of
CHU9D, EQ-5D-Y-3L, HUI2, and HUI3. The heterogeneity of pub-
lished studies means that the evidence was based on studies
across a range of countries, populations, and conditions, using
different study designs, different languages, different value sets,
and different statistical techniques. The wide variation in studies
makes it difficult to synthesize the evidence to generate a
consistent picture of the overall performance of each measure. The
evidence included several studies with small sample sizes that
may not have been powered to detect statistical significance, and
there were only a relatively small number of studies within the
same condition. Evidence for CHU9D was based on a limited
number of studies (n = 12), as well as evidence assessing
responsiveness (n = 14). Only HUI2 performed strongly for test-
retest reliability. None of the measures performed strongly for
interrater reliability between child self-report and parent proxy
report (though CHU9D was not assessed), suggesting there is
reason for concern about the comparability of self-report and
proxy report responses to measure HRQL of children and
adolescents.
More studies assessed the psychometric performance of HUI3
than the other measures, but the evidence of HUI3 was more
mixed. This means that for HUI3 there was a large number of
studies finding evidence of good psychometric performance, but
the proportion of studies that did not find evidence of good psy-
chometric performance was larger than for the other measures.
HUI2 was also assessed in a large number of studies, though the
performance was mixed. In contrast, EQ-5D-Y-3L and CHU9D were
assessed in fewer studies, but the proportion of studies that found
evidence of good psychometric performance was larger.
For EQ-5D-Y-3L there were the same number of studies
assessing performance in general population and clinical popu-
lation samples, and performance was similar across these different
samples. Although the performance of EQ-5D-Y-3L was assessed
by a similar number of studies with clinical samples and general
population samples, CHU9D was mainly assessed in general





























UK value set UUUUUUU67 UUUU U7
EQ-5D-
Y-3L















HUI2 Dimensions UU77 UUU UU7 U777 U UUUU77
Canadian
value set
UUUUUUU677 UUUUUUU66 UUU677 UU677 UU
UK value set U6 U U










Note.U Evidence indicating significant performance. 7 Property was examined but no significant evidence was found. 6 Evidence was mixed or inconclusive evidence
was found. Each symbol represents the findings of one study assessing that psychometric property. Where studies assessed multiple psychometric properties, a symbol
is recorded for each psychometric property assessed.
CHU9D indicates Child Health Utility; HUI2, Health Utilities Index Mark 2; HUI3, Health Utilities Index Mark 3.
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population samples and HUI2 and HUI3 were mainly assessed in
clinical population samples. To inform resource allocation de-
cisions using health technology assessment, it is important that
these generic preference-based measures have good performance
across different conditions; however, it is also important that
these generic preference-based measures have good performance
in general population samples to enable accurate evaluations of
the health of general population samples. Therefore evidence
across both clinical samples and general population samples is
important, and it does not follow that good psychometric per-
formance in one condition or even in clinical population samples
necessarily means that the preference-based measure also has
good psychometric performance in general population samples.
For EQ-5D-Y-3L there is no official value set, and the good
psychometric performance that was identified is based mainly on
the performance on the dimensions. Although it could be antici-
pated that a utility index would have the same psychometric
performance, this can only be confirmed through data analyses. A
value set may not have sufficiently large differences in utility
decrements for different severity levels of each dimension.
Few studies assessed measures within the same clinical area;
however, even where there were multiple studies within a clinical
area the evidence was limited. For example, 3 studies assessed the
performance of measures in patients with asthma: 2 assessed EQ-
5D-Y-3L35,64 and 1 assessed HUI2 and HUI3.65 EQ-5D-Y-3L was
found to have known-group validity and convergent validity, with
no assessment of responsiveness, reliability, acceptability, or
feasibility. HUI2 and HUI3 were found to have convergent validity,
but the study assessed and found no evidence for known-group
validity, responsiveness, or interrater reliability and found evi-
dence of test-retest reliability for HUI2 but not HUI3. On the basis
of these findings it is difficult to recommend use of either measure
over the other because for EQ-5D-Y-3L there is limited evidence
available but the evidence that is available suggests good perfor-
mance, whereas for HUI2 and HUI3 there is wider evidence
available but the evidence is mixed. Equally, although the evi-
dence is mixed, it is difficult to determine whether this is affected
by the sample size of 91. Differences in samples may also poten-
tially affect results.
Some studies had small sample sizes, with 28 out of the 76
studies having a sample size less than 100. Sample size was not
been used to assess the studies, but it should be taken into
consideration that some studies may not have found significant
evidence of the psychometric performance because of the sample
size, meaning that the result may not be indicative of the per-
formance of the measure. In particular for HUI2 and HUI3 this may
have affected the results because for HUI2 15 of 26 studies
assessing performance had sample sizes less than 100 and for
HUI3 18 of 43 studies had sample sizes less than 100. In the
literature there are no clear guidelines or accepted practice about
how to generate sample sizes for studies assessing psychometric
performance of patient-reported outcome measures66 nor, to our
knowledge, preference-based measures.
The review assessed the performance of child- and adolescent-
specific preference-based measures deemed appropriate for
informing UK public policy and hence did not assess the perfor-
mance of all child- and adolescent-specific preference-based
measures. The literature search included search terms to identify
studies assessing AQoL-6D and EQ-5D-Y-5L but identified only 1
relevant study for each measure. The one study assessing AQoL-6D
examined known-group validity, for which evidence was found.23
The one study assessing EQ-5D-Y-5L examined test-retest reli-
ability of the dimensions, for which evidence was found.24 The
review did not include Adolescent Health Utility Measure, AQoL-
6D, EQ-5D-Y-5L, 15D, 16D, 17D, or QWB, and it is recommended
that the psychometric performance of these measures are
reviewed to inform researchers and policy makers worldwide in
their selection of appropriate child- and adolescent-specific pref-
erence-based measures.
Methodologic limitations of the review include potential
missing studies of child and adolescent preference-based mea-
sures in mixed adolescent and adult populations because of the
pediatrics filter applied in the database search. Statistical mapping
analyses were not included in the review because mapping as-
sessments are undertaken to generate predictions rather than
assess association per se, though it is recognized that mapping
analyses can provide some evidence of associations between
measures. Content validity of the measures was not assessed as
part of the review, though it is recognized that this is an important
consideration when deciding which measure to use. Studies that
administered 1 or more measures and summarized their results
were not included in the review unless they assessed psycho-
metric properties. It is possible that some relevant studies may not
have been captured in our search if they did not use the vocab-
ulary of responsiveness or validity, for example, even though they
reported change over time or difference across treatments.
Appropriateness of the statistical analyses undertaken was also
not assessed. In addition, psychometric performance data were
single extracted rather than double extracted (with the exception
of 3 studies). Quality assessment of the studies was not under-
taken, though we have reported where there was a small sample
size.
Conclusion
The review of published evidence on the psychometric per-
formance of a selection of child- and adolescent-specific generic
preference-based measures found that EQ-5D-Y-3L has the largest
proportion of evidence of good psychometric performance out of
the studies that have examined its psychometric performance,
followed by CHU9D; however, the majority of the evidence related
to EQ-5D-Y-3L is based on dimensions, and the same psychometric
performance of any utility index is not guaranteed. This review
enables researchers and policy makers to identify critical evidence
gaps in the performance of these measures, and it is hoped that
knowing this will encourage collection of this psychometric evi-
dence. Further research is recommended to provide greater evi-
dence both on psychometric performance of the measure
(dimensions and utilities) administered by self-report and proxy
report and assessed by the age of the child. The review tables are
informative in indicating patient populations where the psycho-
metric performance of 1 or more measures was assessed and
providing an overview of the evidence found. Concerns were
raised about the comparability of self-report and proxy responses
to measure HRQL of children and adolescents.
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